Compare Abbott Laboratories (ABT) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Vanguard Total International Stock Index Fund ETF — how do they compare? Abbott Laboratories trades at $95.15 (market cap $166.94B), while Vanguard Total International Stock Index Fund ETF trades at $84.22. The key difference: Abbott Laboratories pays a 2.63% dividend while Vanguard Total International Stock Index Fund ETF pays none, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | VXUS | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $87.06 |
52-Week Low | $82.57 | $68.24 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
VXUS trades at $86.17, up 1.57% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides diversified international equity exposure across developed and emerging markets, holding over 8,700 stocks. Recent news highlights its role in portfolio diversification amid high U.S. valuations, with Vanguard surpassing iShares as the largest ETF provider in June 2026.
VXUS offers a strategic hedge against U.S. market concentration, trading at a discount to domestic peers. Key risks include currency fluctuations, geopolitical tensions, and emerging market volatility. Analyst sentiment is positive due to broad diversification and cost efficiency, though performance depends on global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
